News
LTRN
3.280
-0.91%
-0.030
Weekly Report: what happened at LTRN last week (1028-1101)?
Weekly Report · 21h ago
Press Release: Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Dow Jones · 4d ago
Weekly Report: what happened at LTRN last week (1021-1025)?
Weekly Report · 10/28 11:32
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Barchart · 10/23 07:45
Weekly Report: what happened at LTRN last week (1014-1018)?
Weekly Report · 10/21 11:28
Lantern Pharma granted fast track designation for LP-184
TipRanks · 10/15 13:16
LANTERN PHARMA INC - PHASE 1B/2A TRIAL FOR RECURRENT GBM TO START LATE 2024
Reuters · 10/15 13:07
Weekly Report: what happened at LTRN last week (1007-1011)?
Weekly Report · 10/14 12:00
Weekly Report: what happened at LTRN last week (0930-1004)?
Weekly Report · 10/07 11:48
Weekly Report: what happened at LTRN last week (0923-0927)?
Weekly Report · 09/30 11:40
BUZZ-U.S. STOCKS ON THE MOVE-US energy sector, gold miners, AeroVironment
Reuters · 09/23 18:23
BUZZ-U.S. STOCKS ON THE MOVE-Meta, US energy sector, gold miners
Reuters · 09/23 16:32
BUZZ-Lantern Pharma up on FDA's rare pediatric disease tag for cancer therapy
Reuters · 09/23 14:32
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184
Dow Jones · 09/23 12:39
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
NASDAQ · 09/23 12:23
LANTERN PHARMA ANNOUNCES THREE U.S. FDA RARE PEDIATRIC DISEASE DESIGNATIONS GRANTED TO LP-184 IN MULTIPLE ULTRA RARE CHILDREN’S CANCERS
Reuters · 09/23 12:00
Weekly Report: what happened at LTRN last week (0916-0920)?
Weekly Report · 09/23 11:39
Weekly Report: what happened at LTRN last week (0909-0913)?
Weekly Report · 09/16 11:28
Weekly Report: what happened at LTRN last week (0902-0906)?
Weekly Report · 09/09 11:40
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.